October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference

Transcription

1 The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com

2 Perspectives in Thoracic Oncology, now in its 23 rd year, is back again from October 12 13, Designed for those interested in the treatment of thoracic cancer, this two-day meeting promises to cover the latest updates and most essential information from a broad scope of topics, including: Smoking cessation Liquid biopsy Lung cancer screening Locally advanced non-small cell lung cancer (NSCLC) Early-stage NSCLC Adjuvant therapy Mesothelioma Squamous cell carcinoma Thymic tumors The new staging system Advanced NSCLC Supportive therapy Biomarkers and targeted therapy immunotherapy Conference Chair Corey J. Langer, MD Director of Thoracic Oncology Reserve your seat before September 13 to get the best rates. thoraciccancermeeting.com

3 Join us in New York this fall and take part in the crucial conversation surrounding hot topics in thoracic oncology. Those who may benefit from the program, include: As a nurse practitioner specializing in lung cancer, I look forward to the Perspectives in Thoracic Oncology conference each year. I am never disappointed, as the topics span from screening and smoking cessation to various treatment modalities, as well as updates on trials. I credit this annual conference with the practice improvements that our multidisciplinary team makes annually. We look forward to attending in the fall of Medical and Radiation Oncologists Thoracic Surgeons Nurses Diagnostic Radiologists Pathologists April Plank, DNP The Center for Lung Cancer Screening and Prevention Stony Brook, NY Pharmacists Pulmonologists Researchers Other healthcare professionals interested in the care of patients with thoracic malignancies 12.0 AMA/CME credits available.

4 SCIENTIFIC AGENDA Friday, October 12, :00 AM Welcome and Introduction Corey J. Langer, MD, FACP Session I: Introductory Lectures for the New Millennium 8:05 AM Pre-Session Audience Survey 8:10 AM Vaping and Electronic Cigarettes: Is There a Risk for Lung Cancer? 8:30 AM Updated Guidelines for Molecular Testing and Immune Marker Testing in Lung Cancer 8:50 AM The Role of Liquid Biopsies in Thoracic Malignancies 9:10 AM Question & Answer Session 9:25 AM Post-Session Audience Survey Session II: Early-Stage NSCLC 9:30 AM Pre-Session Audience Survey 9:35 AM Novel Techniques for the Detection and Management of Early-Stage NSCLC 10:15 AM Question & Answer Session 10:35 AM Post-Session Audience Survey 10:40 AM Break 9:55 AM Adjuvant Therapy: Current Practice and Emerging Strategies for Early-Stage NSCLC Session III: Locally Advanced NSCLC: The Marriage of Medical, Radiation, and Surgical Oncology 11:00 AM Pre-Session Audience Survey 11:05 AM Locally Advanced NSCLC: Standards and Challenges 11:25 AM Radiation Approaches for Locally Advanced NSCLC: Rethinking Modern Technology 11:45 AM Surgical Dilemmas in the Management of Locally Advanced NSCLC 12:05 PM Question & Answer Session 12:20 PM Post-Session Audience Survey 12:30 PM Lunch Session IV: Special Topics in Lung Cancer 2:00 PM Pre-Session Audience Survey 2:05 PM Squamous NSCLC: Are We Growing the Seeds of Progress? 2:25 PM Integrating Emerging Therapies into Current Treatment Algorithms for SCLC: Case-Based Panel Discussion 2:45 PM Break 3:05 PM Mesothelioma: Old Approaches, New Directions 3:25 PM Managing Patient Expectation in The Era of DCM (Direct to Consumer Marketing) 3:45 PM Question & Answer Session 4:00 PM Post-Session Audience Survey 4:15 PM Adjourn Perspectives in Thoracic Oncology October 12 13, 2018, New York, New York

5 Saturday, October 13, :00 AM Welcome and Introduction Corey J. Langer, MD, FACP Session V: Biomarkers and Targeted Therapy I 8:10 AM Pre-Session Audience Survey 8:15 AM Heterogeneity of NSCLC and Precipitating Oncogenic Driver Mutations 8:30 AM Targeted Treatment With EGFR TKIs: Front Line Options 9:05 AM Interactive Case-Based Panel Discussion 9:20 AM Question & Answer Session 9:35 AM Post-Session Audience Survey 9:40 AM Break 8:45 AM Understanding, Preventing, and Delaying EGFR Resistance in The Era of Osimertinib Session VI: Biomarkers and Targeted Therapy II 10:10 AM Pre-Session Audience Survey 10:15 AM EML4/ALK and ROS-1: How Do We Sequence Therapies? 10:35 AM Potential and Progress in Targeting Less Common Markers: HER2, BRAF, KRAS, MET, TRK, and RET 10:55 AM SCLC: Will Immunotherapy Finally Make A Difference? 11:15 AM Post-Session Audience Survey 11:25 AM Lunch Session VII: Immunotherapy and Lung Cancer I 1:05 PM Overview of The Immunotherapy Landscape for Lung Cancer 1:25 PM First-Line Therapy in NSCLC: Immunotherapy Alone or in Combination with Chemotherapy? 1:45 PM Emerging Biomarkers for Immunotherapy and Thoracic Malignancies 2:05 PM Interactive Case-Based Panel Discussion 2:25 PM Post-Session Audience Survey 2:30 PM Break Session VIII: Immunotherapy and Lung Cancer II 3:00 PM Pre-Session Audience Survey 3:05 PM Emerging Immunotherapies for NSCLC: Extending Beyond PD-1 and PD-L1 Inhibitors 3:25 PM Exporting Immunotherapy to the Curative Setting 4:05 PM Interactive Case-Based Panel Discussion 4:25 PM Question & Answer Session 4:40 PM Post-Session Audience Survey 4:45 PM Adjourn 3:45 PM Monitoring, Managing, and Mitigating Immune-Related Adverse Events Reserve your seat before September 13 to get the best rates. thoraciccancermeeting.com

6 PROGRAM FACULTY Charu Aggarwal, MD, MPH Joshua Bauml, MD Abigail T. Berman, MD, MSCE, Erica L. Carpenter, MBA, PhD Jessica S. Donington, MD NYU Langone Health New York, New York Beth Eaby-Sandy, MSN, CRNP Martin J. Edelman, MD Fox Chase Cancer Center Shirish M. Gadgeel, MD University of Michigan Ann Arbor, Michigan Corey L. Langer, MD Leslie A. Litzky, MD Jim L. Mulshine, MD Rush University Chicago, Illinois For full faculty list, visit thoraciccancermeeting.com. ACCREDITATION STATEMENTS CONTINUING EDUCATION Imedex is accredited by the ACCME to provide continuing medical education for physicians. In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. CREDIT STATEMENTS PHYSICIANS Imedex designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. MAINTENANCE OF CERTIFICATION - ABIM Successful completion of this CME activity enables a participant to earn up to 12.0 MOC points towards the American Board of Internal Medicine s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. The deadline to claim MOC points is December 13, ABIM Diplomates will be asked to provider their identification number and DOB. PHARMACY This live, knowledge-based activity (Universal Activity Number JA L01-P) has been approved for a maximum of 12.0 contact hours (1.2 CEUs). The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is December 13, Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a posttest and/or evaluation for each activity or session attended. NURSING This continuing nursing education activity awards 12.0 contact hours. This activity will also award pharmacotherapeutic contact hours, however the final assignment of these contact hours will be announced once all content has been approved. Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.0 contact hours. PHYSICIAN ASSISTANTS NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 12.0 AAPA Category 1 Credits. PAs should only claim credit commensurate with the extent of their participation. Perspectives in Thoracic Oncology October 12 13, 2018, New York, New York

7 Accommodations New York Marriott Marquis 1535 Broadway New York, New York Located right in the heart of Times Square Within walking distance of great restaurants, shopping, and entertainment Boasts some of the largest hotel rooms and suites in New York City Discounted Group Rate: $349 per night Conference Rates Physician, PhD, Pharmacist All other medical professionals (NP, PA, Nurses, Residents, Students) Pharmaceutical Industry* DISCOUNTED 7/13/2018 9/13/2018 $399 $149 $650 REGULAR After 9/13/2018 $499 $199 To register for the meeting & book your accommodations, visit thoraciccancermeeting.com.

8 October 12 13, 2018 New York Marriott Marquis New York, New York Rainwater Drive, Suite 600, Alpharetta, GA 30009, USA Reserve your seat before September 13 to get the best rates: thoraciccancermeeting.com